Chapter/Section Purchase

1 Opioid-Induced Constipation Market Overview
1.1 Product Overview and Scope of Opioid-Induced Constipation
1.2 Opioid-Induced Constipation Segment by Type
1.2.1 Global Opioid-Induced Constipation Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Methylnaltrexone Bromide
1.2.3 Lubiprostone
1.2.4 Naloxegol
1.2.5 Others
1.3 Opioid-Induced Constipation Segment by Application
1.3.1 Global Opioid-Induced Constipation Sales Comparison by Application: (2021-2027)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Opioid-Induced Constipation Market Size Estimates and Forecasts
1.4.1 Global Opioid-Induced Constipation Revenue 2016-2027
1.4.2 Global Opioid-Induced Constipation Sales 2016-2027
1.4.3 Opioid-Induced Constipation Market Size by Region: 2016 Versus 2021 Versus 2027

2 Opioid-Induced Constipation Market Competition by Manufacturers
2.1 Global Opioid-Induced Constipation Sales Market Share by Manufacturers (2016-2021)
2.2 Global Opioid-Induced Constipation Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Opioid-Induced Constipation Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Opioid-Induced Constipation Manufacturing Sites, Area Served, Product Type
2.5 Opioid-Induced Constipation Market Competitive Situation and Trends
2.5.1 Opioid-Induced Constipation Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Opioid-Induced Constipation Players Market Share by Revenue
2.5.3 Global Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Opioid-Induced Constipation Retrospective Market Scenario by Region
3.1 Global Opioid-Induced Constipation Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Opioid-Induced Constipation Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Opioid-Induced Constipation Market Facts & Figures by Country
3.3.1 North America Opioid-Induced Constipation Sales by Country
3.3.2 North America Opioid-Induced Constipation Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Opioid-Induced Constipation Market Facts & Figures by Country
3.4.1 Europe Opioid-Induced Constipation Sales by Country
3.4.2 Europe Opioid-Induced Constipation Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Opioid-Induced Constipation Market Facts & Figures by Region
3.5.1 Asia Pacific Opioid-Induced Constipation Sales by Region
3.5.2 Asia Pacific Opioid-Induced Constipation Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Opioid-Induced Constipation Market Facts & Figures by Country
3.6.1 Latin America Opioid-Induced Constipation Sales by Country
3.6.2 Latin America Opioid-Induced Constipation Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Opioid-Induced Constipation Market Facts & Figures by Country
3.7.1 Middle East and Africa Opioid-Induced Constipation Sales by Country
3.7.2 Middle East and Africa Opioid-Induced Constipation Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Opioid-Induced Constipation Historic Market Analysis by Type
4.1 Global Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
4.2 Global Opioid-Induced Constipation Revenue Market Share by Type (2016-2021)
4.3 Global Opioid-Induced Constipation Price by Type (2016-2021)

5 Global Opioid-Induced Constipation Historic Market Analysis by Application
5.1 Global Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
5.2 Global Opioid-Induced Constipation Revenue Market Share by Application (2016-2021)
5.3 Global Opioid-Induced Constipation Price by Application (2016-2021)

6 Key Companies Profiled
6.1 Takeda Pharmaceuticals
6.1.1 Takeda Pharmaceuticals Corporation Information
6.1.2 Takeda Pharmaceuticals Description and Business Overview
6.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolio
6.1.5 Takeda Pharmaceuticals Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Corporation Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Bayer Opioid-Induced Constipation Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Sanofi Opioid-Induced Constipation Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Mallinckrodt
6.4.1 Mallinckrodt Corporation Information
6.4.2 Mallinckrodt Description and Business Overview
6.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Mallinckrodt Opioid-Induced Constipation Product Portfolio
6.4.5 Mallinckrodt Recent Developments/Updates
6.5 Salix (Bausch Health)
6.5.1 Salix (Bausch Health) Corporation Information
6.5.2 Salix (Bausch Health) Description and Business Overview
6.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Salix (Bausch Health) Opioid-Induced Constipation Product Portfolio
6.5.5 Salix (Bausch Health) Recent Developments/Updates
6.6 AstraZeneca
6.6.1 AstraZeneca Corporation Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.6.4 AstraZeneca Opioid-Induced Constipation Product Portfolio
6.6.5 AstraZeneca Recent Developments/Updates
6.7 Progenics Pharmaceuticals
6.6.1 Progenics Pharmaceuticals Corporation Information
6.6.2 Progenics Pharmaceuticals Description and Business Overview
6.6.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolio
6.7.5 Progenics Pharmaceuticals Recent Developments/Updates
6.8 Purdue Pharm
6.8.1 Purdue Pharm Corporation Information
6.8.2 Purdue Pharm Description and Business Overview
6.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Purdue Pharm Opioid-Induced Constipation Product Portfolio
6.8.5 Purdue Pharm Recent Developments/Updates
6.9 Nektar Therapeutics
6.9.1 Nektar Therapeutics Corporation Information
6.9.2 Nektar Therapeutics Description and Business Overview
6.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Nektar Therapeutics Opioid-Induced Constipation Product Portfolio
6.9.5 Nektar Therapeutics Recent Developments/Updates
6.10 Daiichi Sankyo
6.10.1 Daiichi Sankyo Corporation Information
6.10.2 Daiichi Sankyo Description and Business Overview
6.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Daiichi Sankyo Opioid-Induced Constipation Product Portfolio
6.10.5 Daiichi Sankyo Recent Developments/Updates
6.11 Prestige
6.11.1 Prestige Corporation Information
6.11.2 Prestige Opioid-Induced Constipation Description and Business Overview
6.11.3 Prestige Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Prestige Opioid-Induced Constipation Product Portfolio
6.11.5 Prestige Recent Developments/Updates
6.12 GSK
6.12.1 GSK Corporation Information
6.12.2 GSK Opioid-Induced Constipation Description and Business Overview
6.12.3 GSK Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.12.4 GSK Opioid-Induced Constipation Product Portfolio
6.12.5 GSK Recent Developments/Updates
6.13 Shionogi
6.13.1 Shionogi Corporation Information
6.13.2 Shionogi Opioid-Induced Constipation Description and Business Overview
6.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Shionogi Opioid-Induced Constipation Product Portfolio
6.13.5 Shionogi Recent Developments/Updates

7 Opioid-Induced Constipation Manufacturing Cost Analysis
7.1 Opioid-Induced Constipation Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Opioid-Induced Constipation
7.4 Opioid-Induced Constipation Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Opioid-Induced Constipation Distributors List
8.3 Opioid-Induced Constipation Customers

9 Opioid-Induced Constipation Market Dynamics
9.1 Opioid-Induced Constipation Industry Trends
9.2 Opioid-Induced Constipation Growth Drivers
9.3 Opioid-Induced Constipation Market Challenges
9.4 Opioid-Induced Constipation Market Restraints

10 Global Market Forecast
10.1 Opioid-Induced Constipation Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Opioid-Induced Constipation by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Opioid-Induced Constipation by Type (2022-2027)
10.2 Opioid-Induced Constipation Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Opioid-Induced Constipation by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Opioid-Induced Constipation by Application (2022-2027)
10.3 Opioid-Induced Constipation Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Opioid-Induced Constipation by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Opioid-Induced Constipation by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer